Clinical Trial: A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.

U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07619066) titled 'A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.' on May 19.

Brief Summary: An international, multicenter, two-stage optimal Simon's design, single-arm phase II clinical trial to evaluate zongertinib plus fulvestrant combination therapy in participants with hormone receptor-positive/HER2-negative advanced breast cancer harboring HER2 mutations.

Study Start Date: Oct. 04, 2026

Study Type: INTERVENTIONAL

Condition: Advanced Breast Cancer Hormone Receptor Positive / HER2-negative Breast Cancer HER2 Mutation

Intervention: DRUG: Zongertin...